Summary
Cencora, Inc. reported robust revenue growth for the nine months ended June 30, 2024, driven by a significant increase in its U.S. Healthcare Solutions segment. This growth was fueled by higher unit volumes, particularly in GLP-1 class drugs for diabetes and weight loss, alongside increased sales of specialty products and COVID-19 vaccines. While gross profit saw a healthy increase, profit margins in the U.S. segment slightly contracted due to a higher mix of lower-margin GLP-1 products, though this was partially offset by higher-margin COVID-19 vaccine sales. The company's operating expenses also increased, impacted by higher distribution, selling, and administrative costs, as well as litigation and opioid-related expenses. Despite these pressures, overall segment operating income showed positive growth, particularly in the U.S. segment. Cencora also highlighted strong cash flow from operations, which was bolstered by effective working capital management, particularly an extended accounts payable cycle. The company continued its share repurchase program and maintained its quarterly dividend. Key financial considerations for investors include the ongoing strength in revenue, the impact of the GLP-1 drug trend on margins, and the significant ongoing liability related to opioid litigation, which continues to be managed with substantial reserves. The company's liquidity remains strong with significant availability under its credit facilities.
Financial Highlights
55 data points| Revenue | $74.24B |
| Cost of Revenue | $71.83B |
| Gross Profit | $2.41B |
| SG&A Expenses | $1.38B |
| Operating Income | $672.48M |
| Net Income | $483.46M |
| EPS (Basic) | $2.44 |
| EPS (Diluted) | $2.42 |
| Shares Outstanding (Basic) | 198.26M |
| Shares Outstanding (Diluted) | 200.05M |
Key Highlights
- 1Revenue increased by 11.2% to $214.9 billion for the nine months ended June 30, 2024, primarily driven by the U.S. Healthcare Solutions segment's 12.1% growth.
- 2Gross profit for the nine months ended June 30, 2024, increased by 10.6% to $7.4 billion, reflecting increased sales across both segments.
- 3Operating income for the nine months ended June 30, 2024, grew by 9.9% to $2.0 billion, with the U.S. Healthcare Solutions segment showing a 13.9% increase.
- 4Net income attributable to Cencora, Inc. for the nine months ended June 30, 2024, was $1.5 billion, an increase from $1.4 billion in the prior year period.
- 5The company generated $2.48 billion in net cash provided by operating activities for the nine months ended June 30, 2024, an increase from $2.08 billion in the prior year.
- 6Cencora has an ongoing share repurchase program with $1.82 billion remaining availability as of June 30, 2024, and declared a quarterly dividend of $0.51 per share.
- 7The company's accrued litigation liability related to opioid litigation was $5.1 billion as of June 30, 2024, with estimated payments over the next 14 years.